JPRN-UMIN000005137已完成3 期
Examination of clinical utility of XX-45(double-balloon enteroscope) - Examination of clinical utility of double-balloon enteroscope
适应症
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 120
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 13years-old 至 79years-old(—)
- 性别
- All
入选标准
- 未提供
排除标准
- •1)Patients with acute abdomen 2)Patients with severe acute inflammation 3)Patients with anaphylaxis to natural rubber 4)Patients in a very bad general condition 5)Patients with suspected intestinal perforation 6)Patients having severe blood clotting defect 7)Patients with severe hepatic function disorder 8)Patients with severe respiratory diseases or circulatory diseases 9)Gravida and possibly pregnant patients 10)Patients who have participated in other clinical trials within 3 months prior to the start of this trial. 11)Patients who do not have the capacity or intention to cooperate with the trial procedures. 12)Patients who have experienced any adverse reactions through the enteroscopy. 13)Patients, the investigator (or the subinvestigator) considers, inappropriate for entry into the trial. 14)Sick or injured persons in life-threatening conditions and from whom it seems difficult to obtain written informed consent for their participation in the trial. 15)Patients with whom insertion of the endoscope has to be conducted via the stoma.
研究者
相似试验
已完成
2 期
A clinical study of Liv.52 GNX tablet in Alcoholic liver diseaseCTRI/2018/03/012751The Himalaya Drug Company40
进行中(未招募)
2 期
Clinical trial of Liv.52 GNX tablets in liver damage due to tuberculosis drugs.CTRI/2018/01/011565The Himalaya Drug Company
进行中(未招募)
不适用
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.EUCTR2004-001449-13-LTBioGeneriX AG90
进行中(未招募)
不适用
Safety and Efficacy of XM 02 in patients with Non-Hodgkin-Lymphoma receiving chemotherapy.Patients with Non-Hodgkin-Lymphoma receiving chemotherapy and developing Neutropenia due to chemotherapy.EUCTR2004-001449-13-HUBioGeneriX AG90
进行中(未招募)
1 期
A phase II Clinical Study of CP-4055 as second line therapy in patients with advanced colorectal cancer - CP4055-202A phase II clinical study of ELACYT as second line therapy in patients with advanced colorectal cancerEUCTR2006-006766-41-GBClavis Pharma ASA42
